Australian-listed bio separations company Memphasys (ASX:MEM) has signed its first MoU with a leading research group based in the US, to take part in in-vitro assessments of the Felix device, adding to its growing list of international partners.
The MoU has been signed with CCRM, a leader in fertility science and treatments based in Colorado USA, to be led by scientific and genetics director Dr Mandy Katz-Jaffe.
Under the agreement, CCRM has committed to work collaboratively with co-inventor of the Felix technology Prof Aitken to validate and confirm the system’s efficacy in separating spermatozoa under clinical conditions.
Commenting on the agreement, Alison Coutts, executive chairman of Memphasys said:
Dr. Mandy Katz-Jaffe and her team from CCRM are renowned for their excellence in reproductive genetics and for achieving outstanding IVF outcomes. We are very excited the CCRM team has agreed to participate in the clinical assessment of the Felix device.
“The recruitment of leading IVF clinics and andrology reference centres in the United States, Europe, Asia and Australia who have initiated their willingness to take part in the Felix assessment is testament to the interest in the device, and recruitment of other leading centres is proceeding well and will be announced shortly,” she said.
The MoU with CCRM adds to the list of organisations lining up to work with Dr Aitken and Memphasys.
The company has recently signed MoUs with two European centres: Stockholm-based leading male infertility clinic and andrology centre, ANOVA, as well as with UCA/GReD, France.
Memphasys has said it is pursuing MoU’s with between ten and fifteen key opinion leaders in the global fertility industry to accurately assess its Felix technology.
